T he overuse of prescription opioids during the past 2 decades has evolved into a major public health issue in the United States. Opioid prescribing increased 350% between 1999 and 2015, from 180 to 640 morphine milligram equivalents per capita (1) , with parallel increases in nonmedical use (2, 3) , neonatal abstinence syndrome (4) , and deaths due to both prescription opioid and heroin overdose (5, 6) . The age-adjusted rate of prescription opioid-related deaths rose from 1.0 to 4.4 deaths per 100 000 population between 1999 and 2016, whereas heroin-related deaths increased nearly 5-fold since 2010, rising from 1.0 to 4.9 deaths per 100 000 population between 2010 and 2016 (7) .
State prescription drug monitoring programs (PDMPs) have been advanced as a critical tool to better inform clinical care, identify illegal prescribing, and reduce prescription opioid-related morbidity and mortality (8, 9) . By 2017, all 50 states and the District of Columbia had an operational PDMP or passed legislation to operate a PDMP. Although PDMPs in the United States have commonalities in terms of centralized statewide data systems that electronically transmit prescription data, the administrative features of PDMPs have varied substantially among states and over time. Programs operate under different regulatory agencies, collect different types of data, require data to be updated at different intervals, and allow access to different groups of people. Despite this variability in PDMP administrative features, previous studies found implementation of these programs to be associated with reductions in the supply (10) , diversion (11) , and misuse of prescription opioids (12) . As such, PDMPs are increasingly promoted as valuable, userfriendly, accurate, and real-time digital resources for providers and law enforcement alike (13, 14) . However, evidence for the effect of PDMPs on drug-induced overdoses remains unclear.
The objective of our review was to systematically search and review the literature to assess whether PDMPs are associated with changes in nonfatal or fatal overdoses; to evaluate whether specific administrative features of PDMPs are differentially associated with these outcomes and, if so, which features are most influential; and to investigate any potential unintended consequences associated with PDMPs.
METHODS Data Sources and Searches
We followed a predefined protocol developed in November 2016 (Supplement 1, available at Annals .org) and structured reporting of the review according to PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines (15 , and ProQuest Dissertations) for titles and abstracts of articles that examined an association between PDMP implementation and nonfatal or fatal drug overdoses. We did not impose a time or language restriction on searches (that is, queries surveyed the entire history of each online database). We included dissertations and peer-reviewed articles, as well as both published and in-process texts. We also examined references from the selected materials to identify additional articles and searched ClinicalTrials.gov. The search was first conducted in November 2016 and repeated in December 2017. All the resulting study titles and abstracts were exported to Covidence, a Web interface developed by Cochrane to systematize the review process (16) . For the search terms and algorithm used in the literature search, see Appendix Table 1 (available at Annals.org).
Study Selection
All titles and abstracts were independently screened by 1 of 3 investigators (D.S.F., J.P.S., or K.K.G.) for eligibility, and those considered relevant by any investigator advanced to the full-text review. We included observational studies published in English if they estimated the beforeand-after change in rates of nonfatal or fatal drug overdoses after a PDMP was implemented within a single U.S. state or in a set of states. No restrictions were placed on sample size or population age. A PDMP was considered implemented when a state operationalized its program and began to collect and distribute data or to make the data available to authorized users.
Data Extraction and Quality Assessment
Two researchers (J.P.S. and K.K.G.) independently read selected articles. Using a standardized article assessment form, they captured data on the specific policy studied; outcome data sources; study design; and results, including point estimates and CIs or P values. After the data were abstracted independently from each study, the 2 researchers reviewed the data for each article to ensure consistency and resolve differences. Disagreements between the researchers were reconciled by the first author (D.S.F.). Finally, 2 investigators independently assessed risk of bias (ROB) for the overdose outcomes reported in each study by using the Cochrane Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) assessment tool (17) . By answering questions provided by ROBINS-I, the investigators assessed ROB within 8 specific bias domains (confounding, selection of participants, classification, deviations from intended interventions, missing data, measurement of outcomes, selection of the reported results, and overall bias), grading each domain as low, moderate, serious, or critical. Disagreements were resolved by consensus.
Data Synthesis and Analysis
Because of substantial heterogeneity in the policies examined and the analytic methods applied, we did not do a meta-analysis. Instead, we performed a qualitative assessment and synthesis using methods outlined by the Agency for Healthcare Research and Quality (18) . We categorized studies into 5 groups: PDMP implementation only, specific administrative features only, both PDMP implementation and specific administrative features, PDMP implementation with other opioid policies, and PDMP robustness. Studies examining only PDMP implementation treated all PDMPs as homogenous programs without considering how their administrative features have varied among states and over time. Studies investigating specific administrative features compared states with a PDMP having a specific feature (such as mandatory registration or use, frequency of reporting, or proactive reporting) with states that either had no PDMP or had a PDMP without the specific feature. Studies of PDMPs implemented with other, associated opioid policies examined the contribution of PDMP features to those policies. Finally, studies examining PDMP robustness presented quantitative ratings of PDMP features according to their potential effectiveness in reducing diversion and overdose. We also examined 3 outcomes: nonfatal overdoses, fatal overdoses, and unintended consequences.
The investigators assessed the overall strength of evidence (SOE), considering 5 domains: study limitations (determined by using ROBINS-I), directness (whether evidence linked interventions directly to a key question in the review), consistency (degree to which studies found the same direction of effect estimates), precision (degree of certainty surrounding an effect estimate), and reporting bias (selective publishing or reporting of findings on the basis of favorability of the direction or magnitude of effect estimates). On the basis of grades from the 5 specific domains, we rated the overall SOE for each intervention and outcome as insufficient, low, moderate, or high.
Role of the Funding Source
The National Institute on Drug Abuse (NIDA) and Bureau of Justice Assistance (BJA) had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript. Figure 1 depicts the literature search and selection process. Seventeen articles met the inclusion criteria; 4 reported nonfatal drug overdoses, and 13 reported fatal drug overdoses. All were published between 2011 and 2018. Three were doctoral dissertations (19 -21) , and 14 were published in peer-reviewed journals (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) . Of note, outcome data from 1 study were extracted from 2 publications (29, 36) . Supplement 2 (available at Annals.org) presents the characteristics and Appendix Table 2 (available at Annals.org) the ROB assessments of the studies.
RESULTS
The Table shows (19, 20, 22, 27, 28) , 1 investigated PDMP implementation with mandated provider review combined with pain clinic laws (25) , and 1 assessed PDMP robustness (26) . The study that examined robustness generated a score of PDMP administrative strength or "robustness" by assigning weights to specific administrative features on the basis of extant evidence, or expert judgment if evidence was lacking, regarding the expected effect of the characteristic on prescribing or overdose, then summing the weights for a PDMP in a given state for a particular year (26) . Among the 7 studies that examined program features, whether alone (22, 24) or in addition to PDMPs in general (19, 20, 22, 27, 28) , mandatory provider use of or registration for the PDMP was the most frequently evaluated administrative feature, with 1 study examining the association with nonfatal overdoses (28) , 4 studies investigating the association with fatal overdoses (20, 22, 24, 27) , and 1 study looking at the association with both nonfatal and fatal overdoses (23) . In addition, 2 studies examined state authorization for providers to access PDMP data (20, 22) , 2 focused on proactive reporting of PDMP data to providers (19, 28) , 1 looked at interstate sharing of PDMP data (19), 3 investigated the frequency of reports (19, 27, 28) , 1 examined PDMP housing agency (19) , and 3 analyzed the monitoring of nonscheduled drugs (19, 27, 28) .
Outcome data on nonfatal and fatal overdoses were obtained from both state-level and national data sets. Two studies used state-level data: 1 used information from the Florida Medical Examiners Commission regarding oxycodone-involved deaths (29) ; the other used data from New York health care facilities on inpatient and emergency department visits (23) . National data on nonfatal overdoses came from either the Drug Abuse Warning Network (30, 31) or Truven Health MarketScan administrative claims (28) , whereas information on fatal drug overdoses was obtained from the Multiple Cause of Death files produced by the National Center for Health Statistics of the Centers for Disease Control and Prevention. International Classification of Diseases, 10th Revision, codes were used to define mortality by state and year on the basis of both the manner and contributing cause of death. Manner of death included drug poisoning that was unintentional (X40 to X44), intentional (X60 to X64), or undetermined (Y10 to Y14). Contributing cause codes were used to identify whether the death was attributed to a prescription opioid analgesic (T40.2 to T40.4) or heroin (T40.1).
PDMP Implementation
All studies examining the association between PDMP implementation and overdose had methodological shortcomings, including inadequate adjustment for time-invariant and time-varying confounding factors and no adjustment for competing laws and policies that might affect overdoses (such as Good Samaritan laws, naloxone distribution, or medical marijuana laws). Three of the studies (all with serious ROB) estimated postimplementation changes in nonfatal overdose rates, finding mixed results (28, 30, 31) . Two studies, 1 analyzing opioid-related overdoses (31) and 1 examining benzodiazepine-related cases (30) , reported no change in nonfatal overdose events after PDMP implementation. Another study reported that PDMP implementation was associated with a 31% decrease (95% CI, 0.56 to 0.87) in prescription opioid-related inpatient and emergency department visits (28) . Differences were found among study samples and years of data examined ( Figure 2) . The studies reporting a nonsignificant change in overdose events analyzed data from 11 metropolitan areas (Boston, Chicago, Denver, Detroit, Houston, Miami-Dade County, Minneapolis-St. Paul, New York City, Phoenix, San Francisco, and Seattle) from 2004 to 2011 (30, 31) ; the study reporting a statistically significant decrease in overdose rates used data from all 50 U.S. states from 2004 to 2014 (28) .
Ten studies (2 low, 6 moderate, and 2 serious ROB) examined the association between PDMP implementation and fatal overdoses. Three reported a decrease (27, 29, 32) , 6 reported no change (19 -22, 33, 34) , and 1 reported an increase in overdose deaths (35) . Studies that found an association between PDMP implementation and a decrease in fatal overdoses restricted their data to a subset of potential U.S. states; 1 study examined oxycodone-related events in Florida (29), and 2 studies excluded early-adopter states (that is, states that instituted a PDMP before 2003) from their analysis (27, 32) . In contrast, the 6 studies that used data from all 50 U.S. states reported that PDMP implementation was not associated with a change in fatal overdoses (19 -22, 33, 34) . All studies that found a decrease or no change in fatal overdoses after PDMP enactment accounted for time-fixed differences between PDMP and non-PDMP states by including a state fixed effect (and did or did not account for time-varying confounders). The study that reported a postimplementation increase in fatal drug overdoses did not adequately adjust for preexisting time-fixed differences between states that did and those that did not enact PDMPs, or for timevarying differences in key factors, such as other policies that might co-occur with PDMP implementation (35) .
Six studies (1 low, 2 moderate, and 3 serious ROB) examined the relationship between PDMP implementation and heroin-related overdose deaths (21, 22, 25, 
PDMP Administrative Features
Nine studies (1 low, 3 moderate, 3 serious, and 2 critical ROB) investigated the relationship between specific PDMP administrative features and nonfatal (23, 28) or fatal (19, 20, (22) (23) (24) (25) (26) (27) overdoses. The studies found reduced rates of fatal overdose in states with programs that shared data with other states (19) , had mandatory provider review (20, 28) , monitored noncontrolled substances (19, 27, 28) , proactively reported patients' controlled substance prescription history to in-state prescribers and licensure boards (herein called proactive reporting) (28) , and updated data at least weekly (27, 28) .
The most frequently analyzed administrative featuremandated provider review of PDMP data-was investigated in 6 studies (20, 22-24, 27, 28) . Three of the studies (low or moderate ROB) specified a fixed effect for each state to examine the association between mandated provider review and drug overdoses after adjustment for time-invariant baseline characteristics. One of these studies found no change in the number of opioid-related deaths (27) , and 2 reported an association between mandated provider review and reduced rates of fatal overdose related to prescription opioids (20, 22) and benzodiazepines (22) , as well as increased rates of overdose death related to heroin and cocaine (22) . The other 3 studies, which did not include state fixed effects to adjust for time-fixed sources of confounding, reported statistically significant increases in opioid-related overdoses (23, 24, 28) .
One study (serious ROB) estimated the combined effect of state pain clinic laws and PDMPs that require providers to query the database (25) . Using data from 38 states from 2006 to 2013, the authors found that these policies together reduced prescription opioid overdose deaths (incident rate ratio, 0.81 [CI, 0.69 to 0.95]) (25) .
One study (serious ROB) estimated the association between PDMP robustness and prescription opioidrelated deaths (26) . The robustness measure of Pardo (26) , grounded in an appreciation of a multifactorial characterization of PDMPs, aimed to quantify the ability of a PDMP to influence provider practices and behaviors. To create this measure, Pardo assigned different weights to administrative features that have a theoretical but subjective basis for changing provider behavior or reducing overdose deaths. For example, access to PDMPs for law enforcement and prosecutors was assigned a weight of 1, whereas requiring that providers check PDMPs before prescribing to a patient was assigned a weight of 4. Next, Pardo calculated scores by summing the total weights for each state by year, with scores ranging from 0 to 23, and found a 1.5% (CI, 0.3% to 30.0%) reduction in the opioid-related overdose death rate for each point assigned to a state's PDMP score. The author estimated that such a reduction would be associated with preventing approximately 300 deaths nationwide per year.
Study Quality and SOE
The Table summarizes the overall SOE regarding PDMPs and drug overdoses. In general, the SOE was stronger for fatal than nonfatal outcomes. A common limitation across comparisons was the small number of studies. For nonfatal outcomes and specific administrative features, the paucity of studies with serious ROB led to estimates that were inconsistent and imprecise, resulting in insufficient SOE. Low-grade evidence was available for the association between PDMP implementation and fatal overdoses. This judgment of low overall SOE for the relationship between PDMP implementation and fatal overdoses was based on the studies with low to moderate ROB, which were precise and consistent. In addition, low-grade evidence was available for the relationship between 4 specific administrative featuresmandatory provider review, provider authorization to access PDMP data, frequency of reporting, and monitoring of nonscheduled drugs-and fatal overdoses.
DISCUSSION
Evidence that PDMP implementation either increases or decreases nonfatal or fatal overdoses is largely insufficient, as is evidence regarding any association between specific PDMP administrative features and nonfatal or fatal overdoses (Table) . The only exception is low-strength evidence of a reduction in fatal overdoses after implementation of PDMPs, specifically those that have mandatory provider review, authorize providers to access PDMP data, update data frequently, and monitor nonscheduled drugs.
Seven studies with low to moderate ROB found inconsistent evidence to support an association between PDMP use and a change in fatal overdoses. The 2 studies that found a decrease in fatal overdoses after PDMP implementation (27, 32) were based on programs started after 2004, when the first Model Prescription Monitoring Program Act was published by the National Alliance for Model State Drug Laws (NAMSDL) (37). Because the NAMSDL act included language promoting the monitoring of nonscheduled drugs, proactive reporting, provider authorization to access PDMP data, and interstate sharing, it is possible that certain, more restrictive, administrative features, common in more recent PDMPs, drove the reductions in overdose deaths that were observed in those studies (27, 32) . Indeed, we found low-strength evidence for a relationship between 4 specific administrative features-mandatory provider review (20, 22) , provider authorization to access data (20, 22) , more frequent reporting (19, 27) , and monitoring of nonscheduled drugs (19, 27) -and a decrease in fatal overdoses. Differences in the influence of certain administrative features suggest that future studies may be more fruitful if they focus on identifying a set of PDMP "best practices" for implementing programs that confer the greatest reduction in overdoses. To identify this set of PDMP best practices, future studies will have to move beyond estimating the effect of specific administrative features or generating a subjective robustness measure and model the complex interplay among different features that bring about the greatest reduction in overdoses, such as latent class analysis or machine learning methods.
Implementation of PDMPs may have unintended negative outcomes-namely, increased rates of heroinrelated overdose. Of the 6 studies examining the relationship between PDMP enactment and heroin-related overdoses, 3 found a statistically significant postimplementation increase in these events (22, 32, 36) . Programs that have adopted best practices, such as realtime reporting and proactive provision of unsolicited patient reports to providers, may reduce the feasibility of "doctor shopping" as well as the overall supply of prescription opioids available from the illicit market. A reduction in black market prescription opioids, although generally viewed as positive, also may generate unanticipated outcomes. For example, an ethnographic study of high-risk users in Philadelphia and San Francisco found that key drivers of the progression from prescription opioid to heroin use are the rising cost of the "pill habit" and heroin's easy availability and comparatively lower cost (38) . As such, changes to either the supply or cost of prescription opioids after a PDMP is instituted might reasonably drive opioid-dependent persons to substitute their preferred prescription opioid with heroin or nonpharmaceutical fentanyl. In that case, policies and laws targeting drug supplies will have to be supplemented by initiatives to better identify persons with opioid dependency and refer them to medication-assisted treatment, or by other evidencebased treatment methods, to mitigate any unintended consequences.
An English-language MEDLINE search up to January 2018 failed to reveal any systematic reviews on the association between PDMP implementation and nonfatal or fatal overdoses. However, we identified 2 narrative reviews (14, 39) that characterized the mechanisms whereby PDMPs might affect population health by influencing prescribing practices and patient behavior; both studies found that PDMPs decrease drug diversion and doctor shopping. Although the state PDMP has become a hallmark health care technology-based intervention to address illegal opioid-prescribing behaviors and their downstream health consequences, our review highlights the dearth of evidence to inform these policies.
Our systematic review had several limitations. All the studies were observational, and many had serious or critical ROB. Studies used many different modeling strategies to account for confounding factors and often examined different years of data and different outcomes. Many did not report effect estimates with CIs or provide sufficient information to calculate a standardized effect estimate. Whether statistically insignificant findings were due to the absence of an association or to insufficient power often was unclear. Although publication bias and selective outcomes reporting are potential limitations, we searched for unpublished trials and outcomes at ClinicalTrials.gov and found no evidence of either of these biases. Although we required studies to be published in English because of limited resources for translation, our review of references from the identified studies did not elucidate any non-English publications that seemed to meet our eligibility criteria.
The limitations in the existing literature suggest a need for several areas of future study. First, more research is needed on the relationship between PDMPs and nonfatal overdoses. Only 4 of the 17 articles included in this review examined nonfatal overdoses. Expanded research into these events will provide a better understanding of how PDMPs affect a broader range of opioid-related harms. Second, research should examine the moderating influence of county-level factors, particularly the influence of area-level income. Residents of higher-income areas are more likely than those of lower-income regions to access prescription opioids through their medical providers and, in the case of prescription opioid misuse, to receive referrals to evidence-based treatment and other care (40, 41) . Thus, PDMPs may affect low-and high-income populations differently, widening existing health disparities (42) . Third, analysis is needed regarding how complementary drug prevention programs (such as medicationassisted therapy, naloxone distribution, and pill mill laws) interact with PDMPs to affect population health. Except for the study by Dowell and colleagues (25) that measured the combined effect of state pain clinic laws and PDMPs, extant studies have focused largely on estimating PDMPs' effect on prescribing behaviors or health outcomes while statistically adjusting for complementary drug prevention programs (such as naloxone distribution initiatives or pill mill laws), instead of investigating whether complementary programs have a synergistic (that is, more than additive) effect on overdose rates. This method of isolating the effect of PDMPs from that of other drug prevention programs probably will have limited utility for decision makers who need information about the health consequences of various options during the policy development process.
We conclude that variations in PDMP features are likely to affect outcomes differently. A PDMP's ability to influence population health probably arises from its unique set of administrative features. Future studies will have to consider this variation in features to develop a set of empirically based best practices that result in the greatest reduction in prescription opioid-related harm and mitigate any potential unintended consequences of PDMPs, such as heroin-related harms. 
